FA-70, a novel selective and irreversible Monoamine Oxidase-A inhibitor: Effect on monoamine metabolism in mouse cerebral cortex

Journal of Pharmacology and Experimental Therapeutics

Volumn 292, Issue 2, 2000, Pages 788-794

  Morón, José A ^a   Pérez, Virgili ^a   Pastó, Manel ^a   Lizcano, José Miguel ^a   Unzeta, Mercedes ^a,b  

^a Facultat de Medicina   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 [N (2 BUTYNYL) N METHYLAMINOMETHYL] 5 HYDROXY 1 METHYLINDOLE; CLORGYLINE; INDOLEAMINE DERIVATIVE; MONOAMINE OXIDASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; MALE; MONOAMINE METABOLISM; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; BIOGENIC MONOAMINES; CEREBRAL CORTEX; CLORGYLINE; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; INDOLES; LIVER; MALE; MICE; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PROTEIN ISOFORMS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 0343920747     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Avila M, Balsa D, Fernández-Alvarez E, Tipton K and Unzeta M (1993) The effect of side chain substitution at positions 2 and 3 of the heterocyclic ring of N-acetylenic analogues of tryptamine as monoamine oxidase inhibitors. Biochem Pharmacol 45:2231-2237.
2. Bach A, Lan N, Johnson C, Abell A, Bembenek E, Kwan S, Seeburg P and Shih J (1988) cDNA cloning of human liver monoamine oxidase A and B: Molecular basis of differences in enzymatic properties. Proc Natl Acad Sci USA 85:4934-4938.
3. Balsa D, Fernández-Alvarez E, Tipton K and Unzeta M (1990) Inhibition of MAO by substituted tryptamine analogues. J Neural Transm 32:103-105.
4. Balsa D, Pérez V, Fernández-Alvarez E and Unzeta M (1994) Kinetic behavior of some acetylenic indolalkylamine derivatives and their corresponding parent amines. J Neural Transm 41:281-285.
5. Butcher S, Frainbother I, Kelly K and Arbuthnott G (1990) Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum. J Neurochem 55:981-988.
6. Charlton C (1997) Depletion of nigrostriatal and forebrain tyrosine hydroxylase by S-adenosylmethionine: A model that may explain the occurrence of depression in Parkinson's disease. Life Sci 61:495-502.
7. Cho S, Duchemin A, Neff N and Hadjiconstantinou M (1996) Modulation of tyrosine hydroxylase and aromatic L-aminoacid decarboxylase after inhibiting monoamine oxidase-A. Eur J Pharmacol 314:51-59.
8. Cho S, Neff N and Hadjiconstantinou M (1997) Regulation of tyrosine hydroxylase and aromatic L-amino acid decarboxylase by dopaminergic drugs. Eur J Pharmacol 323:149-157.
9. Cruces M, Elorriaga C, Fernández-Alvarez E and Nieto O (1988) Synthesis and biochemical properties of N-acetylenic and N-allenic derivatives of 2-aminemethylindoles as selective inhibitors of monoamine oxidase. Pharmacol Res Commun 20:105-107.
10. Curet O, Damoiseau G, Aubin N, Sontag N, Rovei V and Jarreau F (1996) Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. Biochemical profile. J Pharmacol Exp Ther 277:253-264.
11. Ebmeier K and Ebert D (1996) Imaging functional change and dopaminergic activity in depression, in Dopamine Disease States (Beninger RJ, Palomo T and Archer T eds) pp 511-522, Editorial CYM, Madrid, Spain.
12. Feiner A and Waldmeier P (1979) Cumulative effects of irreversible MAO inhibitors in vivo. Biochem Pharmacol 28:995-1002.
13. Finberg J, Wang J, Goldstein D, Kopin I and Bakiewicz A (1995) Influence of selective inhibition of monoamine oxidase A and B on striatal metabolism of L-dopa in hemiparkinsonian rats. J Neurochem 65:1213-1220.
14. Fowler C and Tipton K (1981) Concentration dependence of the oxidation of tyramine by the two forms of rat liver mitochondrial monoamine oxidase. Biochem Pharmacol 30:3329-3332.
15. Gómez N, Unzeta M, Tipton K, Anderson M and O'Carroll AM (1986) Determination of monoamine oxidase concentrations in rat liver by inhibitor binding. Biochem Pharmacol 35:4467-4472.
16. Johnston J (1968) Some observations upon a new inhibitor of monoamine oxidase in human brain. Biochem Pharmacol 17:1285-1297.
17. Kumer S and Vrana K (1996) Intricate regulation of tyrosine hydroxylase activity and gene expression. J Neurochem 67:443-462.
18. Lamensdorf I, Youdim M and Finberg J (1996) Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J Neurochem 67:1532-1539.
19. Lerner P, Major L, Dendel P, Campbell I and Murphy D (1979) Central and peripheral dopamine beta hydroxylase: Responses to long-term treatment with monoamine oxidase inhibitors. Neuropharmacology 19:877-881.
20. Lerner P, Major L, Murphy D, Lipper L and Lovenberg W (1980) Dopamine beta hydroxylase and norepinephrine in human cerebrospinal fluid: Effects of monoamine oxidase inhibitors. Neuropharmacology 18:423-426.
21. 3H]quinpirole binding by a monoamine oxidase inhibitor in subcellular fractions of rat striatum. Life Sci 63:1643-1651.
22. 2 receptors: A potential pharmacological target for nomifensine and tranylcypromine but not other antidepressant treatments. Pharmacol Biochem Behav 51:565-569.
23. Molinengo L and Ghi S (1997) Behavioral and neurochemical effects induced by subchronic L-deprenyl administration. Pharmacol Biochem Behav 68:649-655.
24. Morón J, Pérez V, Marco J, Fernández-Alvarez E and Unzeta M (1998) New 2-[(5-methoxy-1-methylindolyl)]-alkylamine derivatives: The effect of branching and elongation of the side -chain on MAO inhibition. J Enzym Inhib 13:237-251.
25. 4 receptors. J Pharmacol Exp Ther 277:186-192.
26. Okuno S and Fujisawa H (1991) Conversion of tyrosine hydroxylase to stable and inactive form by end products. J Neurochem 57:53-60.
27. Paetsch P and Greenshaw A (1993) 2-Phenylethylamine-induced changes in catecholamine receptor density: Implications for antidepressant drug action. Neurochem Res 18:1015-1022.
28. Pastó M and Sabrià J (1990) Separation and quantification of histamine and N-methylhistamine in brain extracts. Biomed Chromatogr 4:245-248.
29. Pérez V, Marco J, Fernández-Alvarez E and Unzeta M (1996) Kinetic studies of N-allenic analogues of tryptamine as monoamine oxidase inhibitors. J Pharm Pharmacol 48:718-722.
30. Pérez V, Marco JL, Fernandez-Alvarez E and Unzeta M (1999) Relevance of a benzyloxy group in 2-indolyl methylamines in the selective MAO-B inhibition. Br J Pharmacol 127:869-876.
31. Roth R, Wolf M and Deutch A (1987) Neurochemistry of midbrain dopamine systems, in Psychopharmacology: The Third Generation of Progress (Meltzer H ed) p 81, Raven Press, New York.
32. Schoepp D and Azzaro A (1983) Effects of intrastriatal kainic acid injection on dopamine metabolism in rat striatal slices: Evidence for postsynaptic glial cell metabolism by both the A and B forms of monoamine oxidase. J Neurochem 40:1340-1348.
33. Tabor C, Tabor H and Rosenthal S (1954) Purification of amine oxidase from beef plasma. J Biol Chem 208:644-661.
34. 3 receptors inhibit dopamine release. J Pharmacol Exp Ther 270:475-479.
35. 4-like dopamine receptors. Neuropsychopharmacology 17:186-196.
36. Tipton K (1989) Biochemical and Pharmacological Aspects of Depression (Tipton K and Youdim M eds) pp 1-24, Taylor & Francis, London.
37. Walker B and Elmore T (1984) The irreversible inhibition of urokinase kidney cell plasminogen activator plasmin and B-trypsin by carbamoylimidazol. Biochem J 221:277-280.
38. Weissbach H, Smith T, Daly T, Witkop B and Undefriend S (1960) A rapid spectrophometric assay of monoamine oxidase based on the rate of disappearance of kynuramine. J Biol Chem 253:1160-1163.
39. Wolf W, Youdim M and Kuhn D (1985) Does brain 5-HIAA indicate serotonin release or monoamine oxidase activity? Eur J Pharmacol 109:381-387.